Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-25 @ 3:15 PM
Study NCT ID:
NCT04070768
Status:
COMPLETED
Last Update Posted:
2025-05-04
First Post:
2019-08-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Sponsor:
John Quigley
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-06
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-20
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-26
First Submit QC Date:
None
Study First Post Date:
2019-08-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-14
Results First Submit QC Date:
None
Results First Post Date:
2025-05-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-14
Last Update Post Date:
2025-05-04
Last Update Post Date Type:
ACTUAL